Naoko Kuzumaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Naoko Kuzumaki has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Minoru Narita
Department of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Sciences
8 shared publications Michiko Narita
Department of Pharmacology, Hoshi University, School of Pharmacy and Pharmaceuteutical Sciences
4 shared publications- Tsutomu Suzuki
Department of Toxicology Hoshi University School of Pharmacy and Pharmaceutical Sciences Tokyo Japan
4 shared publications - Akira Yamashita
Department of Physiology, Kagoshima University Graduate School of Medical and Dental Science, Kagoshima, 890-8544, Japan
2 shared publications - Daigo Ikegami
Department of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501, Japan
2 shared publications Hideki Tamura
2 shared publications
Latest Publications
- Open Access
- 1 May 2016
- Published by Pharmaceutical Society of Japan in YAKUGAKU ZASSHI
- Vol. 136 (5) , 699-703
Molecular Understanding of the Acquisition of Resistance to Anti-cancer Drugs Associated with the Exacerbation of Cancer
Gefitinib and erlotinib target the ATP cleft in the tyrosine kinase EGFR, which is overexpressed in 40-80 percent of non-small-cell lung cancer (NSCLC) and many other epithelial cancers. However, the application of gefitinib is ultimately limited by the emergence of mutations and other molecular mechanisms conferring drug resistance. Furthermore, it has been considered that acquired resistance to gefitinib is associated with a clinically significant risk of accelerated disease progression. We previously established a new gefitinib-resistant NSCLC cell line, HCC827GR, which harbors the T790M mutation. Using HCC827GR, we found that the inhibition of adenosine A2a receptors of NSCLC regulated cancer proliferation and exacerbation, indicating that adenosine A2a receptors may be new targets for a novel strategy in NSCLC therapy. These findings suggest that multilayered crosstalk between G-protein coupled receptors (GPCRs) and EGFR may play an important role in regulating downstream signaling molecules that are implicated in the development of gefitinib-resistant NSCLC.
- 1 May 2016
- Published by Pharmaceutical Society of Japan in YAKUGAKU ZASSHI
- Vol. 136 (5) , 699-703
Open AccessMolecular Understanding of the Acquisition of Resistance to Anti-cancer Drugs Associated with the Exacerbation of Cancer
Gefitinib and erlotinib target the ATP cleft in the tyrosine kinase EGFR, which is overexpressed in 40-80 percent of non-small-cell lung cancer (NSCLC) and many other epithelial cancers. However, the application of gefitinib is ultimately limited by the emergence of mutations and other molecular mechanisms conferring drug resistance. Furthermore, it has been considered that acquired resistance to gefitinib is associated with a clinically significant risk of accelerated disease progression. We previously established a new gefitinib-resistant NSCLC cell line, HCC827GR, which harbors the T790M mutation. Using HCC827GR, we found that the inhibition of adenosine A2a receptors of NSCLC regulated cancer proliferation and exacerbation, indicating that adenosine A2a receptors may be new targets for a novel strategy in NSCLC therapy. These findings suggest that multilayered crosstalk between G-protein coupled receptors (GPCRs) and EGFR may play an important role in regulating downstream signaling molecules that are implicated in the development of gefitinib-resistant NSCLC.
- 1 January 2016
- Published by Japanese Pharmacological Society in Folia Pharmacologica Japonica
- Vol. 148 (3) , 128-133
Functional role of cortical astrocytes in sleep/affective dysregulation under the chronic pain: analysis by artificial control of astrocytes using optogenetics
慢性疼痛患者は,持続的な痛みを訴える一方で,二次的にうつや不安障害などの精神障害や睡眠障害などの高次脳機能障害を伴うケースが多い.特に,睡眠障害は多くの慢性疼痛患者において共通して認められる症状のひとつであり,逆に睡眠の量や質の悪化が痛みの重症度やうつ・不安障害の悪化に密接に関係している.このような複雑な合併症状による負の連鎖は,「慢性疼痛」という病態を複雑にして患者のQOLを著しく低下させてしまう.こうした現状は,疼痛治療において,疼痛以外の併発・合併症状の改善も考慮に入れて治療を行う必要性を示唆している.そこで我々は,慢性疼痛下における睡眠障害の発現メカニズムについて解析を試みた.神経障害性疼痛モデルマウスを作製し,疼痛下の前帯状回領域において,グルタミン酸遊離量の増加ならびに細胞外GABA濃度の低下を認め,前帯状回領域における神経回路の興奮-抑制のバランスの異常により睡眠障害が惹起されうる可能性を見出した.また,この神経障害性疼痛モデルマウスにおいて,前帯状回領域における神経活動の機能変化にアストロサイトの活性化が一部寄与していることが明らかとなった.さらに,オプトジェネティクス法を駆使した前帯状回アストロサイトの特異的活性化により,睡眠障害が惹起されることを見出した.したがって,慢性疼痛下における睡眠障害の発現の一端には,前帯状回領域における興奮-抑制バランスの調節不全ならびに神経-グリア相互作用の機能異常が関与している可能性が考えられる.
- 1 January 2016
- Published by Japanese Pharmacological Society in Folia Pharmacologica Japonica
- Vol. 148 (3) , 128-133
Functional role of cortical astrocytes in sleep/affective dysregulation under the chronic pain: analysis by artificial control of astrocytes using optogenetics
慢性疼痛患者は,持続的な痛みを訴える一方で,二次的にうつや不安障害などの精神障害や睡眠障害などの高次脳機能障害を伴うケースが多い.特に,睡眠障害は多くの慢性疼痛患者において共通して認められる症状のひとつであり,逆に睡眠の量や質の悪化が痛みの重症度やうつ・不安障害の悪化に密接に関係している.このような複雑な合併症状による負の連鎖は,「慢性疼痛」という病態を複雑にして患者のQOLを著しく低下させてしまう.こうした現状は,疼痛治療において,疼痛以外の併発・合併症状の改善も考慮に入れて治療を行う必要性を示唆している.そこで我々は,慢性疼痛下における睡眠障害の発現メカニズムについて解析を試みた.神経障害性疼痛モデルマウスを作製し,疼痛下の前帯状回領域において,グルタミン酸遊離量の増加ならびに細胞外GABA濃度の低下を認め,前帯状回領域における神経回路の興奮-抑制のバランスの異常により睡眠障害が惹起されうる可能性を見出した.また,この神経障害性疼痛モデルマウスにおいて,前帯状回領域における神経活動の機能変化にアストロサイトの活性化が一部寄与していることが明らかとなった.さらに,オプトジェネティクス法を駆使した前帯状回アストロサイトの特異的活性化により,睡眠障害が惹起されることを見出した.したがって,慢性疼痛下における睡眠障害の発現の一端には,前帯状回領域における興奮-抑制バランスの調節不全ならびに神経-グリア相互作用の機能異常が関与している可能性が考えられる.
- 1 August 2015
- Vol. 35 (4) , 89-95
[Pain and emotional dysregulation: Cellular memory due to pain].
Genetic factors are involved in determinants for the risk of psychiatric disorders, and neurological and neurodegenerative diseases. Chronic pain stimuli and intense pain have effects at a cellular and/or gene expression level, and will eventually induce "cellular memory due to pain", which means that tissue damage, even if only transient, can elicit epigenetically abnormal transcription/translation and post-translational modification in related cells depending on the degree or kind of injury or associated conditions. Such cell memory/transformation due to pain can cause an abnormality in a fundamental intracellular response, such as a change in the three-dimensional structure of DNA, transcription, or translation. On the other hand, pain is a multidimensional experience with sensory-discriminative and motivational-affective components. Recent human brain imaging studies have examined differences in activity in the nucleus accumbens between controls and patients with chronic pain, and have revealed that the nucleus accumbens plays a role in predicting the value of a noxious stimulus and its offset, and in the consequent changes in the motivational state. In this review, we provide a very brief overview of a comprehensive understanding of chronic pain associated with emotional dysregulation due to transcriptional regulation, epigenetic modification and miRNA regulation.
- 1 August 2015
- Vol. 35 (4) , 89-95
[Pain and emotional dysregulation: Cellular memory due to pain].
Genetic factors are involved in determinants for the risk of psychiatric disorders, and neurological and neurodegenerative diseases. Chronic pain stimuli and intense pain have effects at a cellular and/or gene expression level, and will eventually induce "cellular memory due to pain", which means that tissue damage, even if only transient, can elicit epigenetically abnormal transcription/translation and post-translational modification in related cells depending on the degree or kind of injury or associated conditions. Such cell memory/transformation due to pain can cause an abnormality in a fundamental intracellular response, such as a change in the three-dimensional structure of DNA, transcription, or translation. On the other hand, pain is a multidimensional experience with sensory-discriminative and motivational-affective components. Recent human brain imaging studies have examined differences in activity in the nucleus accumbens between controls and patients with chronic pain, and have revealed that the nucleus accumbens plays a role in predicting the value of a noxious stimulus and its offset, and in the consequent changes in the motivational state. In this review, we provide a very brief overview of a comprehensive understanding of chronic pain associated with emotional dysregulation due to transcriptional regulation, epigenetic modification and miRNA regulation.
- Open Access
- 29 October 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (10) , e44368
Multiple Analyses of G-Protein Coupled Receptor (GPCR) Expression in the Development of Gefitinib-Resistance in Transforming Non-Small-Cell Lung Cancer
There is increasing evidence that functional crosstalk between GPCRs and EGFR contributes to the progression of colon, lung, breast, ovarian, prostate and head and neck tumors. In this study, we performed multiple analyses of GPCR expression in a gefitinib-resistant non-small cell lung cancer (NSCLC) cell line, H1975, which harbors an L858R/T790M mutation. To determine the expression profile of mRNAs encoding 384 GPCRs in normal human lung fibroblast (NHLF) and H1975 cells, a GPCR-specific microarray analysis was performed. A heat-map of the microarray revealed considerable differences in the expression of GPCRs between NHLF and H1975 cells. From the GPCR expression list, we selected some GPCR agonists/antagonist to investigate whether the respective ligands could affect the growth of H1975 cells. Among them, treatment with either a selective antagonist of adenosine A2a receptors, which were highly expressed in H1975 cell and another gefitinib-resistant NSCLC cells, HCC827GR cells or “small interfering RNA” (siRNA) targeting adenosine A2a receptors produced a significant decrease in cell viability of both H1975 and HCC827GR cells. Among up-regulated GPCRs in H1975 cells, Gs-, Gi- and Gq-coupled GPCRs were expressed almost equally. Among down-regulated GPCRs, Gi-coupled GPCRs were dominantly expressed in H1975 cells. The present results suggest that multilayered crosstalk between GPCRs and EGFR may play an important role in orchestrating downstream signaling molecules that are implicated in the development of gefitinib-resistant NSCLC.
- 29 October 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (10) , e44368
Open AccessMultiple Analyses of G-Protein Coupled Receptor (GPCR) Expression in the Development of Gefitinib-Resistance in Transforming Non-Small-Cell Lung Cancer
There is increasing evidence that functional crosstalk between GPCRs and EGFR contributes to the progression of colon, lung, breast, ovarian, prostate and head and neck tumors. In this study, we performed multiple analyses of GPCR expression in a gefitinib-resistant non-small cell lung cancer (NSCLC) cell line, H1975, which harbors an L858R/T790M mutation. To determine the expression profile of mRNAs encoding 384 GPCRs in normal human lung fibroblast (NHLF) and H1975 cells, a GPCR-specific microarray analysis was performed. A heat-map of the microarray revealed considerable differences in the expression of GPCRs between NHLF and H1975 cells. From the GPCR expression list, we selected some GPCR agonists/antagonist to investigate whether the respective ligands could affect the growth of H1975 cells. Among them, treatment with either a selective antagonist of adenosine A2a receptors, which were highly expressed in H1975 cell and another gefitinib-resistant NSCLC cells, HCC827GR cells or “small interfering RNA” (siRNA) targeting adenosine A2a receptors produced a significant decrease in cell viability of both H1975 and HCC827GR cells. Among up-regulated GPCRs in H1975 cells, Gs-, Gi- and Gq-coupled GPCRs were expressed almost equally. Among down-regulated GPCRs, Gi-coupled GPCRs were dominantly expressed in H1975 cells. The present results suggest that multilayered crosstalk between GPCRs and EGFR may play an important role in orchestrating downstream signaling molecules that are implicated in the development of gefitinib-resistant NSCLC.
- 1 June 2009
- Vol. 29 (3) , 115-20
[Differences in neuronal toxicity and its molecular mechanisms between methamphetamine and methylphenidate].
Methylphenidate (MPH) is commonly used in the treatment of narcolepsy and attention deficit/hyperactivity disorder (AD/HD) in Japan. MPH has been also known to have psychostimulus effects similar to methamphetamine (METH). In the present study, we compared several effects of MPH to METH. It is well-known that the repeated administration of psychostimulant drugs induces behavioral sensitization. However, MPH failed to induce sensitization to hyperlocomotion, while METH clearly induced behavioral sensitization. Moreover, the METH-induced rewarding effect was maintained even 2 weeks after withdrawal of METH. In contrast, the MPH-induced rewarding effect almost disappeared within 2 weeks after withdrawal of MPH. We next investigated the effect of METH and MPH on astrocytes, which have been known to play an important role in neuronal network systems. Both METH and MPH induced astrocytic activation in limbic neuron/glia cocultures. It is of interest to note that the METH-induced astrocytic activation was still present after an additional 2 days of culture with normal medium. Unlike METH, the MPH-induced astrocytic activation was reversed within 2 days after washout of MPH. Furthermore, high concentration of METH, but not MPH, reduced MAP2a/b positive cells and activated the immunoreactivity of the cleaved caspase-3 in primary cultured limbic neurons, whereas MPH had no such effect. Taken together, the present findings suggest that the psychostimulus effects of METH and MPH occur through different mechanisms.
- 1 June 2009
- Vol. 29 (3) , 115-20
[Differences in neuronal toxicity and its molecular mechanisms between methamphetamine and methylphenidate].
Methylphenidate (MPH) is commonly used in the treatment of narcolepsy and attention deficit/hyperactivity disorder (AD/HD) in Japan. MPH has been also known to have psychostimulus effects similar to methamphetamine (METH). In the present study, we compared several effects of MPH to METH. It is well-known that the repeated administration of psychostimulant drugs induces behavioral sensitization. However, MPH failed to induce sensitization to hyperlocomotion, while METH clearly induced behavioral sensitization. Moreover, the METH-induced rewarding effect was maintained even 2 weeks after withdrawal of METH. In contrast, the MPH-induced rewarding effect almost disappeared within 2 weeks after withdrawal of MPH. We next investigated the effect of METH and MPH on astrocytes, which have been known to play an important role in neuronal network systems. Both METH and MPH induced astrocytic activation in limbic neuron/glia cocultures. It is of interest to note that the METH-induced astrocytic activation was still present after an additional 2 days of culture with normal medium. Unlike METH, the MPH-induced astrocytic activation was reversed within 2 days after washout of MPH. Furthermore, high concentration of METH, but not MPH, reduced MAP2a/b positive cells and activated the immunoreactivity of the cleaved caspase-3 in primary cultured limbic neurons, whereas MPH had no such effect. Taken together, the present findings suggest that the psychostimulus effects of METH and MPH occur through different mechanisms.
- 1 November 2008
- Vol. 28, 169-76
[Difference in tolerance to anti-hyperalgesic effect and its molecular mechanisms between chronic treatment with morphine, fentanyl and oxycodone in a chronic pain-like state].
In the present study, we demonstrated that repeated treatment with fentanyl, but not morphine or oxycodone, causes a rapid desensitization to its ability to block the hyperalgesia associated with the attenuation of mu-opioid receptor resensitization in mice in a chronic pain-like state. In contrast, no such effect was noted in beta-endorphin knockout mice under the chronic pain-like conditions. On the assumption that beta-endorphin might be released within the spinal cord under pain-like conditions, we further examined whether beta-endorphin could be responsible for a desensitization and resensitization of fentanyl under the chronic pain. In cultured cells, unlike morphine, fentanyl and oxycodone induced a robust mu-opioid receptor internalization and, in turn, its resensitization. In the presence of beta-endorphin, the internalized mu-opioid receptor induced by fentanyl, but not oxycodone, remained within the cytosolic component even after washing out. The findings suggest that beta-endorphin could attenuate the resensitization of mu-opioid receptors. This phenomenon may explain the high degree of tolerance to fentanyl that develops with hyperalgesia caused by a chronic pain-like state.
- 1 November 2008
- Vol. 28, 169-76
[Difference in tolerance to anti-hyperalgesic effect and its molecular mechanisms between chronic treatment with morphine, fentanyl and oxycodone in a chronic pain-like state].
In the present study, we demonstrated that repeated treatment with fentanyl, but not morphine or oxycodone, causes a rapid desensitization to its ability to block the hyperalgesia associated with the attenuation of mu-opioid receptor resensitization in mice in a chronic pain-like state. In contrast, no such effect was noted in beta-endorphin knockout mice under the chronic pain-like conditions. On the assumption that beta-endorphin might be released within the spinal cord under pain-like conditions, we further examined whether beta-endorphin could be responsible for a desensitization and resensitization of fentanyl under the chronic pain. In cultured cells, unlike morphine, fentanyl and oxycodone induced a robust mu-opioid receptor internalization and, in turn, its resensitization. In the presence of beta-endorphin, the internalized mu-opioid receptor induced by fentanyl, but not oxycodone, remained within the cytosolic component even after washing out. The findings suggest that beta-endorphin could attenuate the resensitization of mu-opioid receptors. This phenomenon may explain the high degree of tolerance to fentanyl that develops with hyperalgesia caused by a chronic pain-like state.
- 1 February 2008
- Vol. 43 (1) , 13-8
[Implication of neuron-glia interaction in the molecular mechanism of drug dependence].
- 1 February 2008
- Vol. 43 (1) , 13-8
[Implication of neuron-glia interaction in the molecular mechanism of drug dependence].